Gadobutrol Enhanced MRA of the Supra-aortic Vessels "GEMSAV"
Recruiting
Phase 3 Results N/ASummary of Purpose
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required. This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent...
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 22 April 2013.
| 1 May 2011 | 5 Apr 2011 | 1 Oct 2013 | 1 Oct 2013 | 1 Apr 2013 | Unavailable |
| Start Date | First Received | 1st Completion | Completion | Verification | Results |
|---|
Trial Design
- Allocation: Non-Randomized
- Masking: Open Label
- Purpose: Diagnostic
- Endpoint: Safety/Efficacy Study
- Intervention: Single Group Assignment
Contacts
- Bayer Clinical Trials Contact
- For Trial Location Information (Phone Menu Options '3' or '4')
(+)1-888-84 22937
View Trial Locations
Recruitment
- Enrollment: 398
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 69 locations, 13 countries
Principal Investigator
- Bayer Study Director
Bayer
